Restoring mucosal barrier function

Synedgen's first-in-class therapeutics improve patient outcomes by promoting barrier function to repair mucosal injury

Learn about our technology

Protecting the gastrointestinal (GI) tract from injury

Synedgen’s current lead asset is MIIST305, a clinic-ready, orally delivered therapeutic that repairs GI mucosal injury. MIIST305 restores GI function and reduces unchecked inflammation and damage.

Learn about MIIST305

First-In-Class Therapies to Protect, Restore, and Repair the Body

Targeted therapies

Scalable GMP production

Excellent safety profiles

Strong IP Position

Learn about our platform

Our Regenerative Therapeutics

Synedgen's therapeutics have demonstrated efficacy across multiple modalities

See our full portfolio
See our full portfolio